Comment from eXmoor Pharma

Summary: The commenter provides specific technical feedback on the draft guidance, requesting clarification on FDA expectations for assurance levels when no off-target edits are detected. They also suggest that the guidance should include methods to normalize against chromosomal abnormalities that occur independently of genome editing methods.